<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155934</url>
  </required_header>
  <id_info>
    <org_study_id>AA21566</org_study_id>
    <nct_id>NCT01155934</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Ltd. and Janssen Pharmaceutica Products, LP. (Risperdal M-TABTM)1 mg Risperidone Orally Disintegrating Tablets in Healthy Adult Male Volunteers Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the single-dose relative bioavailability study of 1
      mg risperidone orally disintegrating tablets and (Risperdal M-TAB) under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr Reddy's
      Laboratories Ltd. and Janssen Pharmaceutica Products, LP. (Risperdal M-TAB) 1 mg Risperidone
      Orally Disintegrating Tablets in Healthy Adult Male Volunteers under Fed Conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability based on Cmax and AUC parameters</measure>
    <time_frame>1 Month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Risperidone Orally Disintegrating</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperdal M-TAB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone Orally Disintegrating Tablets</intervention_name>
    <description>Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited</description>
    <arm_group_label>Risperidone Orally Disintegrating</arm_group_label>
    <arm_group_label>Risperdal M-TAB</arm_group_label>
    <other_name>(Risperdal M-TAB) tablets of Janssen Pharmaceutica Products</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects were included in the study only if they met all of the following criteria:

          -  Healthy non-smoking (for at least 3 months) adult male volunteers, 18-45 years of age;

          -  Weighing at least 60 kg for males and within 15% of their ideal weights (Table of
             &quot;Desirable Weights of Adults&quot;, Metropolitan Life Insurance Company, 1983);

          -  Medically healthy subjects with clinically normal laboratory profiles and ECGs;

          -  Voluntarily consent to participate in the study.

        Exclusion Criteria:

        Subjects were excluded from the study if there was evidence of any of the following at
        screening or at any time during the study:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic,neurologic, or
             psychiatric disease.

          -  In addition, history or presence of:

          -  alcoholism or drug abuse within the past year;

          -  hypersensitivity or idiosyncratic reaction to risperidone or benzodiazepines or other
             antipsychotic drugs;

          -  seizures;

          -  glaucoma or hypermetropia.

          -  Positive results on Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen
             (HbsAg) and Hepatitis C Virus (HCV) Tests.

          -  Subjects whose sitting blood pressure is less than 110/60 mm Hg at screening or 100/55
             mm Hg before dosing.

          -  Subjects whose pulse is lower than 55 b.p.m. at screening or 50 b.p.m. prior to
             dosing. Subjects whose PR interval is ≥ 190 msec at screening and prior to dosing.

          -  Subjects whose aTe interval is &gt; 450 msec at screening and prior to dosing.

          -  Subjects with a body temperature ≥38°C before dosing.

          -  Subjects who have used any drugs or substances known to be strong inhibitors of CYP
             enzymes (formerly known as cytochrome P450 enzymes) within 10 days prior to the first
             dose.

          -  Subjects who have used any drugs or substances known to be strong inducers of CYP
             enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first
             dose.

          -  Subjects who have been on a special diet (for whatever reason) during the 28 days
             prior to the first dose and throughout the study.

          -  Subjects who, through completion of the study, would have donated in excess of: 500 mL
             of blood in 14 days, or 1500 mL of blood in 180 days, 2500 mL of blood in 1 year.

          -  Subjects who have participated in another clinical trial within 28 days prior to the
             first dose.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geatano Morelli, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma Services</affiliation>
  </overall_official>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2010</study_first_submitted>
  <study_first_submitted_qc>July 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2010</study_first_posted>
  <last_update_submitted>July 1, 2010</last_update_submitted>
  <last_update_submitted_qc>July 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Vice President, Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Crossover</keyword>
  <keyword>Risperidone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

